diagnostics
(49)
Dashlabs.ai
Dashlabs.ai is a Manila-based health-tech company (YC W21) that builds end-to-end, cloud-based software for medical laboratories and clinics. Its DIY laboratory information system connects lab machines, patient records, billing, and results into one platform, and it rose to prominence powering the Philippine Red Cross through millions of COVID-19 RT-PCR tests. Today it serves diagnostic labs, hospitals, dialysis centers, veterinary clinics, and corporate health programs across the Philippines.
Healthlane
Healthlane is an African preventive-health company (Y Combinator W20) that pairs a mobile app with a network of diagnostic laboratories to give people personalized health checkups and screening. Founded by Alain Nteff and Dr. Agbor Ashumanyi Ako, it grew out of the maternal-health service GiftedMom with a goal of catching disease early rather than treating it late.
NOSO LABS
NOSO LABS builds AI agents for field-service technicians in home-services trades - starting with HVAC, plumbing, electrical, and pest control. Its agents automatically follow up on unsold estimates over text, sync notes to the CRM, and route complex jobs to a back-office dashboard, aiming to recover revenue that would otherwise slip through the cracks without adding headcount. Founded in 2025 by Winston Chi and Alex Xi, the San Francisco company is part of Y Combinator's Summer 2025 batch.
Russ Lebovitz
Russ Lebovitz is the co-founder and CEO of Amprion, a precision brain diagnostics company that built the first commercial seed amplification assay for detecting misfolded alpha-synuclein - the protein at the root of Parkinson's disease and other synucleinopathies. An MD/PhD trained at Washington University in St. Louis and a former research physician at Baylor and Fox Chase Cancer Center, Lebovitz spent years chasing prions after the mad cow scare, then pivoted the same detection science toward common neurodegenerative diseases. His SYNTap test won an FDA Breakthrough Device Designation and is now used in clinical trials and patient care to spot brain disease years before symptoms appear.
Sasan Amini
Sasan Amini is the co-founder and CEO of Clear Labs, a San Carlos genomics company that turns next-generation DNA sequencing into a push-button diagnostic for food safety and infectious disease. An Iranian immigrant who left Tehran at 22, he earned a PhD in genomics at Princeton, worked in advanced research at Illumina, and in 2014 set out to make sequencing simple enough for any lab to run. When COVID-19 hit, Clear Labs pivoted its automated platform into SARS-CoV-2 surveillance and reached more than half of U.S. public health labs.
Sheena Menezes
Sheena Menezes is the co-founder and CEO of Simple HealthKit, a Milpitas, California digital health company delivering accurate, affordable at-home diagnostics, treatment, and follow-up care. A biochemist with a PhD from UC Santa Barbara, where she discovered a novel tRNA methylase, she built her career in in-vitro diagnostics before founding Simple HealthKit to close socioeconomic gaps in healthcare access. Born and raised in Kuwait with Indian-Portuguese roots, she has been recognized by Fierce Healthcare as one of its Most Influential Minority Executives in Healthcare and named to Inc.'s 2025 Female Founders 500.
Galatek
Galatek is a Singapore-based automation and AI company building intelligent infrastructure for two sectors where precision and data integrity matter most: life sciences and advanced semiconductor manufacturing. It pairs robotics and machine vision with software - its Abio platform unifying ELN, LIMS, SDMS and lab automation, and its InteVega AI vision platform - to run smart labs and inspect chips. Led by CEO David Tian, Galatek raised roughly US$30 million in a Series A round announced in December 2025 to expand across Europe, North America and Southeast Asia.
Ash
Ash (poweredbyash.com) is a New York-based health technology company that gives healthcare organizations a customizable, white-label platform for at-home diagnostic testing. Founded in 2019 as a direct-to-consumer sexual health testing service for the LGBTQ+ community, Ash pivoted to a B2B model that lets health plans, digital health companies and public health agencies launch branded testing programs across 100+ biomarkers in all 50 states. The company handles kit design, a vetted lab network, multilingual patient engagement, logistics and real-time reporting through one API, and has shipped more than 500,000 kits while helping organizations close care gaps and improve HEDIS and Star Ratings measures.
GlycanAge
GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.
David Stein
David Stein is the co-founder and CEO of Ash (formerly Ash Wellness), a New York-based B2B platform that lets healthcare organizations run their own at-home testing programs. He launched the company out of Cornell Tech's MBA program in 2019 after a frustrating personal experience getting sexual health testing, first building a direct-to-consumer brand for the LGBTQ+ community and then pivoting to white-label infrastructure for providers and payers during COVID-19. Today Ash handles kit design, a CLIA/CAP-certified lab network, logistics, and patient-facing software across all 50 states, and has shipped more than a million test kits.
Oova
Oova is a New York-based women's health company that brings lab-grade hormone testing into the home. Founded in 2017 as a Mount Sinai spinout by Dr. Aparna (Amy) Divaraniya, Oova combines urine test strips, smartphone scanning, and AI to quantitatively measure LH, E3G (estrogen metabolite), and PdG (progesterone metabolite), giving women personalized daily insights for fertility, PCOS, cycle health, and perimenopause. The FDA-registered platform is used by consumers and integrated with hundreds of fertility and women's health clinics through a HIPAA-compliant provider dashboard.
Resonant Sensors Incorporated
Resonant Sensors Incorporated (RSI) is an Arlington, Texas biotechnology company that builds label-free optical biosensor systems based on its patented guided-mode resonance (GMR) technology. Its ResoSens Ultra-Mab Pro benchtop plate reader and disposable Bionetic microarray plates let researchers watch molecular binding interactions in real time, in a standard 96-well format, using tiny sample volumes and no fluorescent labels. RSI targets antibody discovery, epitope binning, hybridoma screening, kinetics and cell-based assays for immunotherapy, diagnostics and life-science research, and also offers analytical contract testing services.
Eric Gornstein
Eric Gornstein is the Chief Executive Officer of Pearl Diagnostics, a Johns Hopkins spinout in Baltimore that makes MycoMEIA, the first FDA-cleared urine test for invasive aspergillosis. A biopharma commercialization veteran with more than 25 years leading product launches, partnering and deal-making across therapeutic areas, he joined Pearl in late 2025 to take the company from FDA clearance to the market and into Europe. Earlier he helped launch Radius Health's first product, Tymlos, and worked in business development and cell therapy partnerships at companies including bit.bio and Talaris Therapeutics.
Feng Xuan
Feng Xuan is a Boston-based scientist-entrepreneur and the co-founder and CEO of Spear Bio, a biotechnology company building ultra-sensitive immunoassays for protein research and early disease diagnostics. He invented the company's core SPEAR (Successive Proximity Extension Amplification Reaction) technology as a Technology Development Fellow at Harvard's Wyss Institute, translating a decade of research in molecular and immuno-diagnostics into a platform that can measure minute quantities of protein biomarkers from sub-microliter samples. Under his leadership, Spear Bio raised an oversubscribed $45 million Series A in 2024 and earned FDA Breakthrough Device Designation for a blood-based pTau 217 test aimed at early Alzheimer's disease detection.
Karius
Karius is a Redwood City, California life-sciences company that turns a single blood draw into a broad infectious-disease diagnosis. Its flagship Karius Test uses microbial cell-free DNA (mcfDNA) sequencing, metagenomics and AI to detect more than 1,000 pathogens - bacteria, DNA viruses, fungi and parasites - often within a day of receiving a sample. Founded in 2014 out of Stephen Quake's lab at Stanford, the company aims to give clinicians a fast, non-invasive alternative to invasive biopsies and slow cultures, with a focus on the immunocompromised patients who need answers most urgently.
Amprion
Amprion is a precision-diagnostics company using Seed Amplification Assay (SAA) technology to detect misfolded proteins - alpha-synuclein, amyloid-beta and tau - in cerebrospinal fluid, giving physicians and drug developers a biological readout of neurodegenerative disease years before symptoms fully emerge. Its flagship SAAmplify-aSYN test (formerly SYNTap) is the first commercially available validated alpha-synuclein SAA, carries an FDA Breakthrough Device Designation, and aims to replace symptom-based guesswork for Parkinson's, Lewy body dementia, Alzheimer's and multiple system atrophy with autopsy-grade certainty.
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
Kryptos Biotechnologies, Inc.
Kryptos Biotechnologies is a Hayward, California life-sciences startup that reinvented the PCR machine around light. Its proprietary photothermal heating uses an optical thin film to convert light into precisely controlled heat, driving an Ultrafast Photonic PCR engine that runs 40 thermal-cycles in under 10 minutes. That engine powers Kuick, a sample-to-answer molecular diagnostics system that delivers lab-grade infectious-disease results at the point of care in roughly 20 minutes. Founded in 2017 and backed by a $10M Series A led by Osang Healthcare, Kryptos is pushing toward U.S. clinical trials and FDA clearance.
Simple HealthKit
Simple HealthKit is a Milpitas, California-based digital health company building end-to-end healthcare infrastructure that unifies at-home and in-clinic diagnostics, a CLIA-certified lab, telehealth, and follow-up care into a single platform. Founded in 2018 by biochemist Sheena Menezes, the company targets health equity by making testing for sexual health, respiratory illness (COVID/flu/RSV), and chronic conditions like diabetes accessible and affordable for underserved populations, selling primarily to health plans, retailers, pharmacies, employers, schools, and public health organizations.
Niamh O'Hara
Niamh O'Hara is the co-founder and CEO of Biotia, a New York healthtech company that pairs next-generation DNA sequencing with AI to identify pathogens causing hard-to-diagnose infections. An evolutionary biologist by training, she spun the company out of Cornell Tech with Weill Cornell geneticist Christopher Mason, runs a CLIA-certified metagenomics lab in Long Island City, and is building what she calls a global microbial sequence database to catch outbreaks before they spread.
Generation Lab
Generation Lab is a San Francisco longevity biotech building SystemAge, a diagnostic that measures how fast your body is actually aging rather than predicting a number. Using DNA methylation analysis of hundreds of biomarkers, it reports biological ages across roughly 19 organ systems from a blood sample, then hands clinicians an actionable plan to track whether interventions are moving the needle. Founded in 2023 by CEO Alina Rui Su, UC Berkeley aging researcher Dr. Irina Conboy, and operator Michael Suswal, the company raised an $11M seed in October 2025 led by Accel and works with 275+ clinics across roughly 18 countries.
HueDx
HueDx is a Philadelphia diagnostics company - formerly Group K Diagnostics - that turns any smartphone camera into a reader for lab-grade, quantitative color-based tests. Its patented HueCard color-correction hardware and AI-powered HueTools/HueCloud software let researchers develop, validate, and deploy paper-based colorimetric assays without proprietary readers or lab infrastructure, aiming to make quantitative results available at the point of care and at home.
Brianna Wronko-Stevens
Brianna Wronko-Stevens is a University of Pennsylvania-trained bioengineer who turned a senior design project into HueDx (formerly Group K Diagnostics), a Philadelphia diagnostics company that reads lab-grade results off a color-changing card and a smartphone camera - no lab, no reader, no waiting days. Inspired by an HIV clinic internship at 17, she built a platform to deliver fast, quantitative results to the patients who can least afford to wait. She founded the company in 2017, served as CEO through a 2023 rebrand and raised millions in funding, then stepped into the Chief Scientific Officer seat to focus on the science.
Hiranjith H
Hiranjith H (also Hiranjith GH) is the Chief Business Officer of Algorithmic Biologics, a Bengaluru-founded deeptech startup that embeds algorithms inside test tubes to make molecular testing dramatically cheaper and faster. Based in the San Francisco Bay Area, he leads the company's commercial operations and US expansion. He spent more than a decade scaling MedGenome's research-services business in the US and earlier built commercialization and analytics strategy for life-sciences clients at Novartis, ZS Associates, and Accenture Management Consulting.
Abram Scientific
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.
AltPep
AltPep is a Seattle biotech company spun out of the University of Washington that is building both diagnostic tests and disease-modifying drugs for amyloid diseases such as Alzheimer's and Parkinson's. Its work is anchored on the alpha-sheet, a non-standard protein structure discovered by founder and CEO Valerie Daggett, which forms in the toxic soluble oligomers that appear at the earliest, pre-symptomatic stages of disease. AltPep's SOBA blood test aims to flag those toxic oligomers years before symptoms, while its SOBIN peptide therapeutics are designed to neutralize them.
Lifeforce
Lifeforce is a personalized health optimization and longevity-medicine platform that pairs at-home blood diagnostics measuring 40-50+ biomarkers with telehealth consults, a personal health coach, and tailored interventions including supplements, hormone protocols, and prescription medication. Co-founded in 2021 by Tony Robbins, Dr. Peter Diamandis, Dugal Bain-Kim, and Joel Jackson, the company aims to help people in midlife take a proactive, data-driven approach to feeling and functioning better rather than waiting for disease to show up.
Bob Wassman
Dr. E. Robert (Bob) Wassman is Chief Medical Officer and Executive Vice President of Clinical Development at MARAbio, a Utah-based diagnostics company building a maternal blood test to identify an autoimmune subtype of autism. A board-certified pediatrician and medical geneticist with more than 40 years in the field, he has served as chief medical officer for a long roster of genetic-testing pioneers including Genzyme Genetics, Ambry Genetics, Rosetta Genomics and Good Start Genetics, repeatedly turning frontier laboratory technology into clinical service across reproductive medicine, cancer, and neurodevelopmental disability.
Charles R. Bridges
Charles R. Bridges, M.D., Sc.D., is Executive Vice President and Chief Scientific Officer at CorVista Health, where he leads the science behind a machine-learning cardiac diagnostic platform. A cardiac surgeon turned engineer-executive, he holds an A.B. in applied physics from Harvard, an M.D. from Harvard Medical School (which he entered at 18), and both an M.S. in electrical engineering and a D.Sc. in chemical engineering from MIT. He was the first African American full professor of surgery at the University of Pennsylvania, served as a technology chief at Johnson & Johnson's Janssen, and in 2022 was elected to the U.S. National Academy of Engineering. His record spans 175 peer-reviewed publications, 15 patents, and more than $10 million in continuous NIH funding.
MARAbio
MARAbio is a Salt Lake City precision-immunology company that built the first-ever blood test to identify Maternal Autoantibody Related Autism (MARA), a biological subtype of autism caused by a mother's own IgG autoantibodies crossing the placenta and binding fetal brain proteins. Founded on more than two decades of research by Dr. Judy Van de Water at the UC Davis MIND Institute, the company's MAR-Autism test screens mothers for specific autoantibody combinations linked to autism risk, and the company is now extending the science toward therapeutics that could neutralize those antibodies before they reach a developing brain.